Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration
Part of paid clinical trials in Fort Worth, Texas.
- Sponsor
- Alcon Research
- Study ID
- NCT01157065
- Phase
- PHASE2
- Status
- Completed
Conditions
- Exudative Age-Related Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- AL-78898A — DRUGInvestigational treatment
- Ranibizumab — DRUGAnti-vascular endothelial growth factor (VEGF) treatment
Study Details
The primary purpose of this study was to demonstrate a biological effect of AL-78898A, as measured by change (reduction) in central subfield (CSF) retinal thickness 4 weeks after a single intravitreal injection, as compared to LUCENTIS.
Key Dates
- First listed
- Jul 5, 2010
- Start date
- Jun 30, 2011
- Status verified
- Apr 2013
- Primary completion
- Apr 30, 2012
- Completion
- Apr 30, 2012
Study Design
- Enrollment
- 99 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: AL-78898ASingle 50-µL (microliter) intravitreal injection with 12 weeks follow-up
- Active Comparator: LucentisSingle 50-µL (microliter) intravitreal injection with 12 weeks follow-up
Primary Outcome Measure
Mean Reduction From Baseline in Central Subfield (CSF) Retinal Thickness at Week 4 [ Time Frame: Week 4 ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Contact Alcon Call Center for Trial Locations | Fort Worth | Texas | 76134 | - |
Find similar trials in Fort Worth, TX
By research site